Prognostic factors for survival with nabpaclitaxel plus gemcitabine in metastatic pancreatic cancer in real-life practice: The ANICE-PaC study

Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life setting may provide useful information to support decision-making processes in routine practice.